Wells Fargo’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$86.6M Sell
1,081,271
-581
-0.1% -$47.9K 0.02% 691
2025
Q4
$92.2M Buy
1,081,852
+234,983
+28% +$19.3M 0.02% 646
2025
Q3
$65.9M Sell
846,869
-64,237
-7% -$5.02M 0.01% 778
2025
Q2
$71.3M Buy
911,106
+45,487
+5% +$3.39M 0.01% 703
2025
Q1
$62.7M Buy
865,619
+21,596
+3% +$1.55M 0.01% 710
2024
Q4
$62.5M Buy
844,023
+81,144
+11% +$5.68M 0.01% 719
2024
Q3
$50.3M Sell
762,879
-90,000
-11% -$6.54M 0.01% 801
2024
Q2
$78.8M Buy
852,879
+30,655
+4% +$2.71M 0.02% 584
2024
Q1
$78.6M Buy
822,224
+134,400
+20% +$11.3M 0.02% 583
2023
Q4
$52.4M Buy
687,824
+19,893
+3% +$1.38M 0.01% 715
2023
Q3
$46.3M Sell
667,931
-231,338
-26% -$18.6M 0.01% 712
2023
Q2
$84.8M Buy
899,269
+37,382
+4% +$3.25M 0.02% 509
2023
Q1
$71.3M Sell
861,887
-50,760
-6% -$3.99M 0.02% 554
2022
Q4
$68.1M Sell
912,647
-114,414
-11% -$8.82M 0.02% 561
2022
Q3
$84.9M Sell
1,027,061
-194,504
-16% -$18.7M 0.03% 447
2022
Q2
$116M Sell
1,221,565
-146,801
-11% -$15.2M 0.04% 374
2022
Q1
$161M Sell
1,368,366
-4,730
-0.3% -$531K 0.04% 339
2021
Q4
$178M Sell
1,373,096
-2,809,638
-67% -$328M 0.04% 316
2021
Q3
$474M Sell
4,182,734
-484,710
-10% -$55.3M 0.1% 189
2021
Q2
$483M Sell
4,667,444
-141,498
-3% -$13.3M 0.11% 188
2021
Q1
$402M Sell
4,808,942
-50,252
-1% -$4.25M 0.09% 213
2020
Q4
$443M Buy
4,859,194
+243,707
+5% +$20.2M 0.11% 186
2020
Q3
$368M Buy
4,615,487
+81,391
+2% +$6.35M 0.1% 190
2020
Q2
$313M Buy
4,534,096
+610,303
+16% +$43.4M 0.09% 213
2020
Q1
$247M Buy
3,923,793
+656,028
+20% +$47.3M 0.09% 222
2019
Q4
$254M Sell
3,267,765
-283,992
-8% -$22.2M 0.07% 278
2019
Q3
$260M Sell
3,551,757
-162,741
-4% -$11.4M 0.07% 258
2019
Q2
$229M Buy
3,714,498
+381,480
+11% +$23.1M 0.07% 295
2019
Q1
$213M Sell
3,333,018
-258,219
-7% -$14.7M 0.06% 306
2018
Q4
$183M Sell
3,591,237
-51,957
-1% -$2.63M 0.06% 308
2018
Q3
$211M Sell
3,643,194
-1,771,497
-33% -$86.6M 0.06% 314
2018
Q2
$263M Sell
5,414,691
-1,296,516
-19% -$60.5M 0.08% 262
2018
Q1
$312M Sell
6,711,207
-250,962
-4% -$10.9M 0.09% 218
2017
Q4
$262M Sell
6,962,169
-682,677
-9% -$25.1M 0.08% 273
2017
Q3
$279M Buy
7,644,846
+1,287,066
+20% +$49.1M 0.09% 236
2017
Q2
$251M Buy
6,357,780
+744,879
+13% +$27.2M 0.08% 256
2017
Q1
$176M Buy
5,612,901
+582,600
+12% +$18.2M 0.06% 336
2016
Q4
$157M Buy
5,030,301
+2,590,638
+106% +$83.9M 0.06% 362
2016
Q3
$98M Buy
2,439,663
+252,669
+12% +$9.52M 0.04% 513
2016
Q2
$72.7M Sell
2,186,994
-1,516,233
-41% -$51.9M 0.03% 588
2016
Q1
$109M Buy
3,703,227
+156,294
+4% +$4.31M 0.04% 441
2015
Q4
$93.4M Sell
3,546,933
-356,823
-9% -$9.27M 0.04% 487
2015
Q3
$92.5M Buy
3,903,756
+2,261,862
+138% +$54.6M 0.04% 490
2015
Q2
$39M Buy
1,641,894
+633,684
+63% +$14.3M 0.02% 945
2015
Q1
$23.9M Buy
1,008,210
+165,222
+20% +$3.71M 0.01% 1210
2014
Q4
$17.9M Buy
842,988
+241,224
+40% +$4.85M 0.01% 1361
2014
Q3
$10.2M Buy
601,764
+1,878
+0.3% +$29.6K ﹤0.01% 1759
2014
Q2
$8.58M Sell
599,886
-692,676
-54% -$9.39M ﹤0.01% 1922
2014
Q1
$16M Buy
1,292,562
+98,490
+8% +$1.14M 0.01% 1426
2013
Q4
$13.1M Sell
1,194,072
-704,232
-37% -$7.94M 0.01% 1534
2013
Q3
$22M Buy
1,898,304
+273,168
+17% +$3.2M 0.01% 1142
2013
Q2
$18.2M Buy
+1,625,136
New +$19.2M 0.01% 1197

Other funds holding EW

Wells Fargo's EW Position: Q1 2026 in Review

Wells Fargo reduced its Edwards Lifesciences (EW) stake by 0.05% in Q1 2026, selling an estimated $47.9K and leaving 1,081,271 shares worth $86.6M. The position accounts for 0.02% of the portfolio, ranked #691.

Wells Fargo first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $483M in Q2 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Wells Fargo held 1,081,271 shares of Edwards Lifesciences worth $86.6M as of Q1 2026.
  • Wells Fargo sold 581 Edwards Lifesciences shares in Q1 2026, an estimated $47.9K.
  • Edwards Lifesciences made up 0.02% of Wells Fargo's portfolio in Q1 2026, its #691 holding.
  • Wells Fargo first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Edwards Lifesciences position peaked at $483M in Q2 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.